Dexamethasone insert reduces time spent planning cataract surgery, counselling patients
Dr Lisa Nijm discusses how utilising a dexamethasone intracanalicular insert after cataract surgery saves time for practices.
Dr Lisa Nijm reports that use of a dexamethasone intracanalicular insert (Dextenza, Ocular Therapeutix) after cataract surgery saves a practice up to 40 hours when compared to a standard postoperative drop routine.
In addition to saving practices time and energy, use of Dextenza increased patient compliance and reduce treatment burden as fewer postoperative counselling sessions were required.
Video transcript
Dr Lisa Nijm: My research that I presented today focuses on utilising a dexamethasone intracanalicular insert to assess whether there's time saved on patient callbacks and surgery planning.
For this study, we collected user experience and feedback on utilising Dextenza for cataract surgery patients compared to using standard postoperative drops.
There were 19 practices in total; they performed an average of 160 cataract surgeries per week when we looked across the practices. And for the study, they had to perform at least 10 cataract surgeries utilising Dextenza.
In analysing the data from the study, were able to see that by utilising Dextenza, staff saved 45% time counselling postoperative patients when utilising Dextenza compared to standard drops. This translated to about 15.5 minutes per patient. And when you looked overall, we're over 40 hours, staff hours, per week, so it is equivalent of one full-time staff per week that was saved by utilising Dextenza.
In addition, the satisfaction rate among the staff was very high for utilising Dextenza, with 95% of staff reporting positive feedback in utilising Dextenza versus conventional drops.
So in conclusion, I think that the results of this study show the benefits to practice of utilising a postoperative steroid regime like Dextenza for a practice to be able to time save and really translate into practical benefits for the practice, where they are not spending as much time counselling patients postoperatively using drops, as well as decreasing the overall burden or expense on the practice and ensuring compliance with patients. Thank you very much.
Note: This transcript has been lighlty edited for clarity.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
